bluebird bio, Inc. (NASDAQ:BLUE) Shares Sold by Summit X LLC

Summit X LLC cut its holdings in shares of bluebird bio, Inc. (NASDAQ:BLUE) by 93.4% during the fourth quarter, HoldingsChannel.com reports. The firm owned 37,644 shares of the biotechnology company’s stock after selling 530,187 shares during the period. Summit X LLC’s holdings in bluebird bio were worth $314,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in BLUE. BNP Paribas Financial Markets increased its position in shares of bluebird bio by 2,270.2% during the third quarter. BNP Paribas Financial Markets now owns 371,224 shares of the biotechnology company’s stock worth $193,000 after purchasing an additional 355,562 shares in the last quarter. FMR LLC increased its position in shares of bluebird bio by 8.1% in the 3rd quarter. FMR LLC now owns 2,481,965 shares of the biotechnology company’s stock valued at $1,289,000 after acquiring an additional 186,903 shares during the period. Barclays PLC increased its position in shares of bluebird bio by 273.7% in the 3rd quarter. Barclays PLC now owns 252,062 shares of the biotechnology company’s stock valued at $130,000 after acquiring an additional 184,605 shares during the period. Geode Capital Management LLC increased its position in shares of bluebird bio by 3.7% in the 3rd quarter. Geode Capital Management LLC now owns 4,683,042 shares of the biotechnology company’s stock valued at $2,433,000 after acquiring an additional 166,771 shares during the period. Finally, Verition Fund Management LLC acquired a new position in shares of bluebird bio in the 3rd quarter valued at $42,000. 87.43% of the stock is owned by institutional investors and hedge funds.

bluebird bio Trading Down 2.5 %

BLUE stock opened at $3.86 on Thursday. The company’s 50-day simple moving average is $6.67 and its 200-day simple moving average is $8.41. The company has a quick ratio of 0.33, a current ratio of 0.51 and a debt-to-equity ratio of 0.37. bluebird bio, Inc. has a 52-week low of $3.56 and a 52-week high of $30.90. The firm has a market cap of $37.53 million, a P/E ratio of -0.10 and a beta of 0.76.

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. JPMorgan Chase & Co. raised bluebird bio from an “underweight” rating to a “neutral” rating in a research report on Monday, February 24th. StockNews.com assumed coverage on bluebird bio in a research report on Wednesday. They issued a “sell” rating on the stock. Barclays upped their target price on bluebird bio from $2.00 to $40.00 and gave the company an “overweight” rating in a research report on Tuesday, December 31st. Royal Bank of Canada reissued a “sector perform” rating and issued a $80.00 target price on shares of bluebird bio in a research report on Friday, November 15th. Finally, Wells Fargo & Company lowered their price target on shares of bluebird bio from $40.00 to $5.00 and set an “equal weight” rating on the stock in a report on Monday, February 24th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $48.10.

bluebird bio Profile

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.